<DOC>
	<DOCNO>NCT01847014</DOCNO>
	<brief_summary>SYMPHONY Extension extension AC-055-401 , multi-center , open-label , single-arm , Phase 3b study macitentan patient Pulmonary Arterial Hypertension psychometrically validate PAH-SYMPACT instrument . The objective ass long-term safety macitentan subject PAH beyond treatment AC-055-401 study .</brief_summary>
	<brief_title>Clinical Study Macitentan Patients With PAH Psychometrically Validate PAH-SYMPACT Instrument</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure . Patients PAH complete study AC055401 Women childbearing potential must : Have negative urine pregnancy test Visit 1 agree perform monthly serum pregnancy test . Agree use two method contraception Visit 1 1 month study drug discontinuation . Patients prematurely discontinue study drug study AC055401 Females lactate pregnant ( positive Visit 1 pregnancy test ) plan become pregnant study Known hypersensitivity macitentan excipients drug class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
	<keyword>psychometric instrument</keyword>
	<keyword>PAH-SYMPACT</keyword>
</DOC>